Filters

Pp-202 manufacturers

Filters

1 products found

pp-202

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
Australia
GMP approvals
TGA
Comments
Indication: Myelofibrosis (MF) — in combination with ruxolitinib in JAK-inhibitor-naïve patients Clinical stage: Phase 2 — ongoing (combination with ruxolitinib) Modality: Small molecule (first-in-class SSAO/VAP-1 inhibitor) Mechanism / Target: First-in-class inhibitor of SSAO (semicarbazide-sensitive amine oxidase) / VAP-1 (vascular adhesion protein-1); reduces inflammatory cell trafficking to the bone marrow, targeting marrow fibrosis and inflammation beyond JAK inhibition alone Route / form: Oral Differentiation: First-in-class SSAO/VAP-1 inhibitor with novel mechanism addressing bone marrow inflammatory trafficking; complementary to JAK inhibition (ruxolitinib); addresses residual disease activity not fully controlled by JAK inhibitors
Manufacturer #39339
Australia-based publicly listed clinical-stage drug-development company built on proprietary small-molecule enzyme chemistry. Rx oral and injectable pipeline targets blood cancers and conditions linked to inflammation and fibrosis. Advances candidates through early- and mid-stage clinical studies with regulatory engagement.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.